NSE: AARTIIND | BSE: 524208

Mid-range Performer

Download real time

457.75 -3.40 (-0.74%)

40.20% Fall from 52W High

624.0K NSE+BSE Volume

NSE 09 Jul, 2025 3:31 PM (IST)

16,595.9

Market Cap

High in industry

1.5

Beta 1Year

Very High Volatility

Aarti Industries Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for AARTIIND, BSE:524208 Aarti Industries Ltd.

Aarti Industries Ltd.

07 Apr 2020

457.75

-0.74%

Pick of the Week

Buy: Aarti Industries Ltd.

Target

Axis Direct

Specialty Chemicals (SC) segment to benefit in near term due to COVID-19 led supply disruptions: With outbreak of coronavirus causing prices of some chemical to move upwards due to short supply that could be positive for Aarti Industries SC division in the near term.

Aarti Industries Ltd. is trading below its 30 day SMA of 469.0

Aarti Industries Ltd.

24 Mar 2020

457.75

-0.74%

Aarti Industries Ltd

Buy: Aarti Industries Ltd.

CD Equisearch

Impacted by shortage of nitric acid, Aarti Industries reported no small stress in its speciality chemicals business EBIT margins for it shrunk to 20.6% in Q3 from a gravity-defying 23.9% in Q2, resulting in flat lining of its EBIT. Wherefore, NCB production plunged 16.1% to 14900 tons while Aarti could churn out just 1666 tons of nitro toluene last quarter when compared to 4000 tons in the same quarter a year ago. Volumes barely showed any buoyancy...

Aarti Industries Ltd. is trading below its 30 day SMA of 469.0

Aarti Industries Ltd.

20 Mar 2020

457.75

-0.74%

Aarti Industries -3QFY20 Result Update

Buy: Aarti Industries Ltd.

Reliance Securities

Revenue from pharma business grew by 3% YoY. Notably, the segment recorded its highest therapies i.e. antihypertensive, cardiovascular, oncology and corticosteroids etc. The company also has a strong pipeline of approvals and visibility to maintain growth momentum. Segmental EBIT grew by 20% YoY in 3QFY20, and we expect similar growth in 4QFY20E as well. Specialty Chemical Biz Slight Decline in Margin...

Promoters pledged 0.01% of shares in last quarter. Total pledge stands at 3.56% of promoter holdings

Aarti Industries Ltd.

18 Mar 2020

457.75

-0.74%

Aarti Industries -3QFY20 Result Update

Buy: Aarti Industries Ltd.

Recommendation

Reliance Securities

Prabhudas Lilladhar increased Sell price target of Aarti Industries Ltd. to 420.0 on 02 Jul, 2025.

Aarti Industries Ltd.

06 Mar 2020

457.75

-0.74%

Event Update:Aarti Inds.

Buy: Aarti Industries Ltd.

Axis Direct

Specialty Chemical division to benefit owing to Coronavirus outbreak in China as it could accelerate the shift of supply chain to India from China

Aarti Industries Ltd. has lost -35.38% in the last 1 Year

Aarti Industries Ltd.

02 Mar 2020

457.75

-0.74%

Ashika - Stock Picks - Aarti Industries Ltd. - March 2020

Buy: Aarti Industries Ltd.

Ashika Research

operations include APIs, intermediates and Xanthene derivatives. It has 11 plants for specialty chemicals and 4 for pharma (2 USFDA and 2 WHO/ GMP). Further, another 2 projects are coming at Dahej SEZ and setting up...

Aarti Industries Ltd. has an average target of 520.17 from 6 brokers.

Aarti Industries Ltd.

17 Feb 2020

457.75

-0.74%

AARTI INDUSTERIES LTD

Accumulate: Aarti Industries Ltd.

Target

Geojit BNP Paribas

AARTI Industries Ltd (ARTO) is a global leader in Benzene based derivative products. The company has a diversified product portfolio with end users in pharma, agrochemicals, specialty polymers, paints & pigments. Q3 revenue declined by 4.5% YoY, as realisation were lower on account of decline in raw material prices (RM)....

Aarti Industries Ltd. is trading above its 200 day SMA of 452.2

Aarti Industries Ltd.

13 Feb 2020

457.75

-0.74%

Q3FY20 Result Update

Buy: Aarti Industries Ltd.

Prabhudas Lilladhar

Next leg of Aarti's growth will ride on start of three long-term contracts worth Rs150bn progressively from Q4FY20. We tweak our estimates by 1-6% to factor in likely jump in profitability given disruption in Chinese supplies even as we moderate the ramp up of new LT contracts. For FY21E. AIL with a diversified product portfolio of 200 products remain well placed to capitalize on rising investment in domestic downstream...

Aarti Industries Ltd. has an average target of 520.17 from 6 brokers.

Aarti Industries Ltd.

13 Feb 2020

457.75

-0.74%

Aarti Industries -3QFY20 Result Update

Hold: Aarti Industries Ltd.

Reliance Securities

Aarti Industries Ltd. has an average target of 520.17 from 6 brokers.

Aarti Industries Ltd.

14 Jan 2020

457.75

-0.74%

BP Equities Pharma and Chemical Result Preview Q3 FY20

Hold: Aarti Industries Ltd.

BP Wealth

US business remains lackluster; extension of acute season led to healthy performance in Domestic market We expect the companies under our pharmaceuticals coverage to report revenue growth of 5.4% in Q3FY20 with 12.6% growth in profitability, driven by strong traction in India and API business. The US revenues are expected to decline by 1.6% YoY , mainly due to high base and lack of meaningful launches. However, strong ramp-up in gTamiflu and steady base business performance in some US focused players can surprise on positive side. Regulatory hurdles continue to impact as the sector received nine warning letters during CY19. With respect to domestic markets, the growth is likely to favour companies with larger presence in acute therapy led by extended acute season. Growth in...

Aarti Industries Ltd. has lost -35.38% in the last 1 Year

Is Aarti Industries Ltd. worth buying?

873 Votes:

Buy 80.76%

Sell 11.45%

Hold 7.79%

RESEARCH REPORTS

Sell SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf